AdrA as a Potential Immunomodulatory Candidate for STING-Mediated Antiviral Therapy That Required Both Type I IFN and TNF-α Production.
Adenoviridae
/ genetics
Animals
Antiviral Agents
/ therapeutic use
Dendritic Cells
/ physiology
Disease Models, Animal
Genetic Vectors
Hepatitis B
/ immunology
Hepatitis B virus
/ physiology
Humans
Immunomodulation
Interferon Type I
/ metabolism
Male
Membrane Proteins
/ genetics
Mice
Mice, Inbred C57BL
Mice, Knockout
Receptor, Interferon alpha-beta
/ genetics
Receptors, Adrenergic, alpha-1
/ genetics
Tumor Necrosis Factor-alpha
/ metabolism
Virus Replication
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
15 01 2021
15 01 2021
Historique:
received:
14
08
2020
accepted:
09
11
2020
pubmed:
11
12
2020
medline:
11
5
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Several dinucleotide cyclases, including cyclic GMP-AMP synthase, and their involvement in STING-mediated immunity have been extensively studied. In this study, we tested five bacterial diguanylate cyclases from the Gram-negative bacterium
Identifiants
pubmed: 33298616
pii: jimmunol.2000953
doi: 10.4049/jimmunol.2000953
doi:
Substances chimiques
Antiviral Agents
0
Ifnar1 protein, mouse
0
Interferon Type I
0
Membrane Proteins
0
Receptors, Adrenergic, alpha-1
0
Sting1 protein, mouse
0
Tumor Necrosis Factor-alpha
0
Receptor, Interferon alpha-beta
156986-95-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
376-385Informations de copyright
Copyright © 2021 by The American Association of Immunologists, Inc.